BioHarvest Sciences Inc (CSE:BHSC) (OTCMKTS:CNVCF) (FRA:8MV) revealed that it has reached a milestone in its production of cannabinoids, with its first cell reservoir producing Cannabis Trichomes, which are the natural micro-factories producing cannabinoids, for the past two years.
The Vancouver-based company’s ground-breaking technology employs the original cannabis plant and its cells as starting material only once, allowing BioHarvest to harvest 13-17 cycles per year, versus an average of four cycles per year through conventional cannabis cultivation methods.
“The company's bioreactors can reliably and continuously produce cannabis cells without the need to source the mother plant, seeds, or any other starting material again,” said the company. This efficiency results from bypassing the "seeding" and "vegetative" stage, usually taking a cannabis plant anywhere between 6-to-13 weeks.
READ: BioHarvest delves into the science behind how its dietary supplement VINIA has anti-aging powers
In addition, BioHarvest's cannabis cells can remain in the flowering stage continuously, in contrast to a typical cannabis flower that dies after nine or 10 weeks of flowering. “In that case, new starting material will need to be sourced and propagated, and new seedlings will be required to be grown through the vegetative stage, once again,” said the company. In sharp contrast, BioHarvest's BioFarming technology does not require the conventional propagation and vegetative stages and provides an unprecedented level of efficiency to the cannabis industry.
"The repeated use of the same cannabis cell reservoir for two years is an unprecedented scientific achievement in the cannabis plant kingdom," said Dr Yochi Hagay, who is the CTO at BioHarvest. "Our ability to keep our cannabis cells in this 'flowering' stage for the past two years versus conventional periods of nine weeks demonstrates the unique efficiency of our technology and puts us on track to reach commercial production using cannabis-based compounds."
Meanwhile, BioHarvest CEO Ilan Sobel said the company is “on track to commercialize its cannabis-based products in H1/2022.”
“The abilities and achievements discussed above take us closer to such a time when we can bring the power of the company's BioFarming technology to the cannabis market. I am pleased with our progress and shall continue to update stakeholders periodically," added Sobel.
Eitan Popper, co-founder of MedReleaf and chairman of BioHarvest's Board of Advisors, noted that BioHarvest achievement is a “testament to the robustness of the company's technology.”
“Reducing the growth cycle and total production time from no less than the conventional 16 weeks to 3-4 weeks, has immense economic and environmental implications," added Popper.
BioHarvest will host a shareholder update webinar on July 8 at 2 pm ET. Participants can register HERE.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive